nodes	percent_of_prediction	percent_of_DWPC	metapath
Etoricoxib—CYP2E1—Dacarbazine—sarcoma	0.108	0.191	CbGbCtD
Etoricoxib—CYP2E1—Mitoxantrone—sarcoma	0.0839	0.148	CbGbCtD
Etoricoxib—PTGS2—Etoposide—sarcoma	0.0811	0.143	CbGbCtD
Etoricoxib—CYP1A2—Dacarbazine—sarcoma	0.0625	0.111	CbGbCtD
Etoricoxib—CYP3A4—Thiotepa—sarcoma	0.0591	0.105	CbGbCtD
Etoricoxib—CYP2E1—Etoposide—sarcoma	0.0529	0.0936	CbGbCtD
Etoricoxib—CYP1A2—Etoposide—sarcoma	0.0306	0.0541	CbGbCtD
Etoricoxib—CYP3A4—Mitoxantrone—sarcoma	0.0254	0.045	CbGbCtD
Etoricoxib—CYP3A4—Vincristine—sarcoma	0.0175	0.0309	CbGbCtD
Etoricoxib—CYP2D6—Doxorubicin—sarcoma	0.0172	0.0304	CbGbCtD
Etoricoxib—CYP3A4—Etoposide—sarcoma	0.016	0.0284	CbGbCtD
Etoricoxib—CYP3A4—Doxorubicin—sarcoma	0.0109	0.0193	CbGbCtD
Etoricoxib—PTGS2—periosteum—sarcoma	0.00337	0.0681	CbGeAlD
Etoricoxib—PTGS2—leg—sarcoma	0.00268	0.0543	CbGeAlD
Etoricoxib—PTGS2—hindlimb—sarcoma	0.0024	0.0485	CbGeAlD
Etoricoxib—MAPK14—embryo—sarcoma	0.00237	0.0481	CbGeAlD
Etoricoxib—PTGS2—cartilage tissue—sarcoma	0.00236	0.0478	CbGeAlD
Etoricoxib—MAPK14—hematopoietic system—sarcoma	0.00212	0.0429	CbGeAlD
Etoricoxib—PTGS2—appendage—sarcoma	0.00206	0.0416	CbGeAlD
Etoricoxib—MAPK14—connective tissue—sarcoma	0.00204	0.0413	CbGeAlD
Etoricoxib—MAPK14—smooth muscle tissue—sarcoma	0.00187	0.0378	CbGeAlD
Etoricoxib—MAPK14—skin of body—sarcoma	0.00184	0.0373	CbGeAlD
Etoricoxib—MAPK14—uterus—sarcoma	0.0016	0.0324	CbGeAlD
Etoricoxib—MAPK14—lymphoid tissue—sarcoma	0.00149	0.0302	CbGeAlD
Etoricoxib—MAPK14—tendon—sarcoma	0.0014	0.0284	CbGeAlD
Etoricoxib—MAPK14—bone marrow—sarcoma	0.00136	0.0275	CbGeAlD
Etoricoxib—PTGS2—endothelium—sarcoma	0.00124	0.0251	CbGeAlD
Etoricoxib—MAPK14—testis—sarcoma	0.00116	0.0235	CbGeAlD
Etoricoxib—CYP2C9—mammary gland—sarcoma	0.00115	0.0232	CbGeAlD
Etoricoxib—MAPK14—liver—sarcoma	0.0011	0.0222	CbGeAlD
Etoricoxib—CYP2C19—hematopoietic system—sarcoma	0.000901	0.0182	CbGeAlD
Etoricoxib—MAPK14—lymph node—sarcoma	0.000842	0.017	CbGeAlD
Etoricoxib—CYP1A2—hematopoietic system—sarcoma	0.000736	0.0149	CbGeAlD
Etoricoxib—PTGS2—myometrium—sarcoma	0.00071	0.0144	CbGeAlD
Etoricoxib—CYP2C9—hematopoietic system—sarcoma	0.000699	0.0141	CbGeAlD
Etoricoxib—CYP2E1—seminal vesicle—sarcoma	0.000697	0.0141	CbGeAlD
Etoricoxib—PTGS2—embryo—sarcoma	0.000683	0.0138	CbGeAlD
Etoricoxib—CYP2E1—hematopoietic system—sarcoma	0.000662	0.0134	CbGeAlD
Etoricoxib—PTGS2—seminal vesicle—sarcoma	0.000641	0.013	CbGeAlD
Etoricoxib—PTGS2—hematopoietic system—sarcoma	0.00061	0.0123	CbGeAlD
Etoricoxib—PTGS2—connective tissue—sarcoma	0.000587	0.0119	CbGeAlD
Etoricoxib—PTGS2—smooth muscle tissue—sarcoma	0.000537	0.0109	CbGeAlD
Etoricoxib—CYP3A4—hematopoietic system—sarcoma	0.000533	0.0108	CbGeAlD
Etoricoxib—PTGS2—skin of body—sarcoma	0.00053	0.0107	CbGeAlD
Etoricoxib—CYP2D6—hematopoietic system—sarcoma	0.000524	0.0106	CbGeAlD
Etoricoxib—CYP2C19—liver—sarcoma	0.000467	0.00945	CbGeAlD
Etoricoxib—CYP2E1—lymphoid tissue—sarcoma	0.000466	0.00943	CbGeAlD
Etoricoxib—PTGS2—uterus—sarcoma	0.00046	0.00932	CbGeAlD
Etoricoxib—CYP2E1—tendon—sarcoma	0.000438	0.00887	CbGeAlD
Etoricoxib—PTGS2—lymphoid tissue—sarcoma	0.000429	0.00869	CbGeAlD
Etoricoxib—PTGS2—tendon—sarcoma	0.000403	0.00817	CbGeAlD
Etoricoxib—PTGS2—bone marrow—sarcoma	0.000391	0.00791	CbGeAlD
Etoricoxib—CYP1A2—liver—sarcoma	0.000381	0.00772	CbGeAlD
Etoricoxib—CYP2E1—testis—sarcoma	0.000363	0.00734	CbGeAlD
Etoricoxib—CYP2C9—liver—sarcoma	0.000362	0.00733	CbGeAlD
Etoricoxib—CYP2E1—liver—sarcoma	0.000343	0.00694	CbGeAlD
Etoricoxib—PTGS2—liver—sarcoma	0.000316	0.00639	CbGeAlD
Etoricoxib—CYP2D6—testis—sarcoma	0.000287	0.00581	CbGeAlD
Etoricoxib—CYP3A4—liver—sarcoma	0.000276	0.00559	CbGeAlD
Etoricoxib—CYP2D6—liver—sarcoma	0.000272	0.0055	CbGeAlD
Etoricoxib—Asthenia—Dactinomycin—sarcoma	0.00025	0.00113	CcSEcCtD
Etoricoxib—Feeling abnormal—Mitoxantrone—sarcoma	0.000249	0.00113	CcSEcCtD
Etoricoxib—Blood creatinine increased—Doxorubicin—sarcoma	0.000249	0.00113	CcSEcCtD
Etoricoxib—Pruritus—Thiotepa—sarcoma	0.000248	0.00112	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Mitoxantrone—sarcoma	0.000247	0.00112	CcSEcCtD
Etoricoxib—Thrombocytopenia—Etoposide—sarcoma	0.000246	0.00111	CcSEcCtD
Etoricoxib—Abdominal pain—Vincristine—sarcoma	0.000246	0.00111	CcSEcCtD
Etoricoxib—Skin disorder—Etoposide—sarcoma	0.000245	0.00111	CcSEcCtD
Etoricoxib—Pancreatitis—Epirubicin—sarcoma	0.000243	0.0011	CcSEcCtD
Etoricoxib—Orthostatic hypotension—Doxorubicin—sarcoma	0.000243	0.0011	CcSEcCtD
Etoricoxib—PTGS2—lymph node—sarcoma	0.000242	0.0049	CbGeAlD
Etoricoxib—Angina pectoris—Epirubicin—sarcoma	0.000242	0.00109	CcSEcCtD
Etoricoxib—Urticaria—Mitoxantrone—sarcoma	0.00024	0.00109	CcSEcCtD
Etoricoxib—Breast disorder—Doxorubicin—sarcoma	0.00024	0.00109	CcSEcCtD
Etoricoxib—Anorexia—Etoposide—sarcoma	0.00024	0.00109	CcSEcCtD
Etoricoxib—Diarrhoea—Thiotepa—sarcoma	0.00024	0.00108	CcSEcCtD
Etoricoxib—Abdominal pain—Mitoxantrone—sarcoma	0.000239	0.00108	CcSEcCtD
Etoricoxib—Toxic epidermal necrolysis—Doxorubicin—sarcoma	0.000239	0.00108	CcSEcCtD
Etoricoxib—Aspartate aminotransferase increased—Doxorubicin—sarcoma	0.000239	0.00108	CcSEcCtD
Etoricoxib—Bronchitis—Epirubicin—sarcoma	0.000239	0.00108	CcSEcCtD
Etoricoxib—Diarrhoea—Dactinomycin—sarcoma	0.000238	0.00108	CcSEcCtD
Etoricoxib—Gastritis—Doxorubicin—sarcoma	0.000235	0.00106	CcSEcCtD
Etoricoxib—Alanine aminotransferase increased—Doxorubicin—sarcoma	0.000234	0.00106	CcSEcCtD
Etoricoxib—Muscular weakness—Doxorubicin—sarcoma	0.000234	0.00106	CcSEcCtD
Etoricoxib—Dizziness—Thiotepa—sarcoma	0.000232	0.00105	CcSEcCtD
Etoricoxib—Abdominal distension—Doxorubicin—sarcoma	0.000231	0.00105	CcSEcCtD
Etoricoxib—Upper respiratory tract infection—Epirubicin—sarcoma	0.000231	0.00104	CcSEcCtD
Etoricoxib—Hypersensitivity—Vincristine—sarcoma	0.000229	0.00104	CcSEcCtD
Etoricoxib—Photosensitivity reaction—Epirubicin—sarcoma	0.000227	0.00102	CcSEcCtD
Etoricoxib—Weight increased—Epirubicin—sarcoma	0.000226	0.00102	CcSEcCtD
Etoricoxib—Pancreatitis—Doxorubicin—sarcoma	0.000225	0.00102	CcSEcCtD
Etoricoxib—Dyspnoea—Etoposide—sarcoma	0.000224	0.00101	CcSEcCtD
Etoricoxib—Hyperglycaemia—Epirubicin—sarcoma	0.000224	0.00101	CcSEcCtD
Etoricoxib—Somnolence—Etoposide—sarcoma	0.000224	0.00101	CcSEcCtD
Etoricoxib—Angina pectoris—Doxorubicin—sarcoma	0.000224	0.00101	CcSEcCtD
Etoricoxib—Hypersensitivity—Mitoxantrone—sarcoma	0.000223	0.00101	CcSEcCtD
Etoricoxib—Asthenia—Vincristine—sarcoma	0.000223	0.00101	CcSEcCtD
Etoricoxib—Vomiting—Thiotepa—sarcoma	0.000223	0.00101	CcSEcCtD
Etoricoxib—Pneumonia—Epirubicin—sarcoma	0.000223	0.00101	CcSEcCtD
Etoricoxib—Infestation—Epirubicin—sarcoma	0.000221	0.001	CcSEcCtD
Etoricoxib—Infestation NOS—Epirubicin—sarcoma	0.000221	0.001	CcSEcCtD
Etoricoxib—Vomiting—Dactinomycin—sarcoma	0.000221	0.001	CcSEcCtD
Etoricoxib—Rash—Thiotepa—sarcoma	0.000221	0.000999	CcSEcCtD
Etoricoxib—Bronchitis—Doxorubicin—sarcoma	0.000221	0.000998	CcSEcCtD
Etoricoxib—Dermatitis—Thiotepa—sarcoma	0.000221	0.000998	CcSEcCtD
Etoricoxib—Headache—Thiotepa—sarcoma	0.00022	0.000993	CcSEcCtD
Etoricoxib—Stevens-Johnson syndrome—Epirubicin—sarcoma	0.000219	0.000992	CcSEcCtD
Etoricoxib—Rash—Dactinomycin—sarcoma	0.000219	0.000992	CcSEcCtD
Etoricoxib—Decreased appetite—Etoposide—sarcoma	0.000219	0.00099	CcSEcCtD
Etoricoxib—Renal failure—Epirubicin—sarcoma	0.000217	0.000983	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Etoposide—sarcoma	0.000217	0.000983	CcSEcCtD
Etoricoxib—Asthenia—Mitoxantrone—sarcoma	0.000217	0.000982	CcSEcCtD
Etoricoxib—Fatigue—Etoposide—sarcoma	0.000217	0.000981	CcSEcCtD
Etoricoxib—Neuropathy peripheral—Epirubicin—sarcoma	0.000217	0.000981	CcSEcCtD
Etoricoxib—Jaundice—Epirubicin—sarcoma	0.000216	0.000975	CcSEcCtD
Etoricoxib—Stomatitis—Epirubicin—sarcoma	0.000216	0.000975	CcSEcCtD
Etoricoxib—Constipation—Etoposide—sarcoma	0.000215	0.000973	CcSEcCtD
Etoricoxib—Pain—Etoposide—sarcoma	0.000215	0.000973	CcSEcCtD
Etoricoxib—Urinary tract infection—Epirubicin—sarcoma	0.000215	0.000972	CcSEcCtD
Etoricoxib—Conjunctivitis—Epirubicin—sarcoma	0.000215	0.000972	CcSEcCtD
Etoricoxib—Upper respiratory tract infection—Doxorubicin—sarcoma	0.000213	0.000965	CcSEcCtD
Etoricoxib—Diarrhoea—Vincristine—sarcoma	0.000213	0.000961	CcSEcCtD
Etoricoxib—Haematuria—Epirubicin—sarcoma	0.000211	0.000954	CcSEcCtD
Etoricoxib—Photosensitivity reaction—Doxorubicin—sarcoma	0.00021	0.000948	CcSEcCtD
Etoricoxib—Hepatobiliary disease—Epirubicin—sarcoma	0.000209	0.000946	CcSEcCtD
Etoricoxib—Weight increased—Doxorubicin—sarcoma	0.000209	0.000945	CcSEcCtD
Etoricoxib—Epistaxis—Epirubicin—sarcoma	0.000209	0.000944	CcSEcCtD
Etoricoxib—Nausea—Thiotepa—sarcoma	0.000208	0.000941	CcSEcCtD
Etoricoxib—Sinusitis—Epirubicin—sarcoma	0.000208	0.000939	CcSEcCtD
Etoricoxib—Feeling abnormal—Etoposide—sarcoma	0.000207	0.000938	CcSEcCtD
Etoricoxib—Hyperglycaemia—Doxorubicin—sarcoma	0.000207	0.000937	CcSEcCtD
Etoricoxib—Diarrhoea—Mitoxantrone—sarcoma	0.000207	0.000936	CcSEcCtD
Etoricoxib—Nausea—Dactinomycin—sarcoma	0.000207	0.000934	CcSEcCtD
Etoricoxib—Pneumonia—Doxorubicin—sarcoma	0.000206	0.000931	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Etoposide—sarcoma	0.000206	0.000931	CcSEcCtD
Etoricoxib—Dizziness—Vincristine—sarcoma	0.000206	0.000929	CcSEcCtD
Etoricoxib—Infestation NOS—Doxorubicin—sarcoma	0.000205	0.000926	CcSEcCtD
Etoricoxib—Infestation—Doxorubicin—sarcoma	0.000205	0.000926	CcSEcCtD
Etoricoxib—Stevens-Johnson syndrome—Doxorubicin—sarcoma	0.000203	0.000918	CcSEcCtD
Etoricoxib—Renal failure—Doxorubicin—sarcoma	0.000201	0.00091	CcSEcCtD
Etoricoxib—Neuropathy peripheral—Doxorubicin—sarcoma	0.000201	0.000907	CcSEcCtD
Etoricoxib—Urticaria—Etoposide—sarcoma	0.0002	0.000904	CcSEcCtD
Etoricoxib—Haemoglobin—Epirubicin—sarcoma	0.0002	0.000903	CcSEcCtD
Etoricoxib—Stomatitis—Doxorubicin—sarcoma	0.0002	0.000902	CcSEcCtD
Etoricoxib—Jaundice—Doxorubicin—sarcoma	0.0002	0.000902	CcSEcCtD
Etoricoxib—Abdominal pain—Etoposide—sarcoma	0.000199	0.0009	CcSEcCtD
Etoricoxib—Urinary tract infection—Doxorubicin—sarcoma	0.000199	0.0009	CcSEcCtD
Etoricoxib—Conjunctivitis—Doxorubicin—sarcoma	0.000199	0.0009	CcSEcCtD
Etoricoxib—Hepatitis—Epirubicin—sarcoma	0.000199	0.000898	CcSEcCtD
Etoricoxib—Haemorrhage—Epirubicin—sarcoma	0.000199	0.000898	CcSEcCtD
Etoricoxib—Hypoaesthesia—Epirubicin—sarcoma	0.000198	0.000894	CcSEcCtD
Etoricoxib—Vomiting—Vincristine—sarcoma	0.000198	0.000893	CcSEcCtD
Etoricoxib—Pharyngitis—Epirubicin—sarcoma	0.000197	0.000891	CcSEcCtD
Etoricoxib—Urinary tract disorder—Epirubicin—sarcoma	0.000196	0.000887	CcSEcCtD
Etoricoxib—Rash—Vincristine—sarcoma	0.000196	0.000886	CcSEcCtD
Etoricoxib—Dermatitis—Vincristine—sarcoma	0.000196	0.000885	CcSEcCtD
Etoricoxib—Oedema peripheral—Epirubicin—sarcoma	0.000196	0.000885	CcSEcCtD
Etoricoxib—Haematuria—Doxorubicin—sarcoma	0.000195	0.000883	CcSEcCtD
Etoricoxib—Connective tissue disorder—Epirubicin—sarcoma	0.000195	0.000883	CcSEcCtD
Etoricoxib—Urethral disorder—Epirubicin—sarcoma	0.000195	0.00088	CcSEcCtD
Etoricoxib—Headache—Vincristine—sarcoma	0.000195	0.00088	CcSEcCtD
Etoricoxib—Hepatobiliary disease—Doxorubicin—sarcoma	0.000194	0.000875	CcSEcCtD
Etoricoxib—Epistaxis—Doxorubicin—sarcoma	0.000193	0.000873	CcSEcCtD
Etoricoxib—Vomiting—Mitoxantrone—sarcoma	0.000192	0.00087	CcSEcCtD
Etoricoxib—Sinusitis—Doxorubicin—sarcoma	0.000192	0.000868	CcSEcCtD
Etoricoxib—Visual impairment—Epirubicin—sarcoma	0.000191	0.000866	CcSEcCtD
Etoricoxib—Rash—Mitoxantrone—sarcoma	0.000191	0.000863	CcSEcCtD
Etoricoxib—Dermatitis—Mitoxantrone—sarcoma	0.000191	0.000862	CcSEcCtD
Etoricoxib—Headache—Mitoxantrone—sarcoma	0.00019	0.000857	CcSEcCtD
Etoricoxib—Erythema multiforme—Epirubicin—sarcoma	0.000188	0.000849	CcSEcCtD
Etoricoxib—Eye disorder—Epirubicin—sarcoma	0.000186	0.000839	CcSEcCtD
Etoricoxib—Hypersensitivity—Etoposide—sarcoma	0.000185	0.000839	CcSEcCtD
Etoricoxib—Tinnitus—Epirubicin—sarcoma	0.000185	0.000837	CcSEcCtD
Etoricoxib—Haemoglobin—Doxorubicin—sarcoma	0.000185	0.000835	CcSEcCtD
Etoricoxib—Nausea—Vincristine—sarcoma	0.000185	0.000835	CcSEcCtD
Etoricoxib—Flushing—Epirubicin—sarcoma	0.000184	0.000834	CcSEcCtD
Etoricoxib—Cardiac disorder—Epirubicin—sarcoma	0.000184	0.000834	CcSEcCtD
Etoricoxib—Haemorrhage—Doxorubicin—sarcoma	0.000184	0.000831	CcSEcCtD
Etoricoxib—Hepatitis—Doxorubicin—sarcoma	0.000184	0.000831	CcSEcCtD
Etoricoxib—Hypoaesthesia—Doxorubicin—sarcoma	0.000183	0.000827	CcSEcCtD
Etoricoxib—Pharyngitis—Doxorubicin—sarcoma	0.000182	0.000825	CcSEcCtD
Etoricoxib—Urinary tract disorder—Doxorubicin—sarcoma	0.000181	0.000821	CcSEcCtD
Etoricoxib—Oedema peripheral—Doxorubicin—sarcoma	0.000181	0.000819	CcSEcCtD
Etoricoxib—Asthenia—Etoposide—sarcoma	0.000181	0.000817	CcSEcCtD
Etoricoxib—Connective tissue disorder—Doxorubicin—sarcoma	0.000181	0.000817	CcSEcCtD
Etoricoxib—Angiopathy—Epirubicin—sarcoma	0.00018	0.000815	CcSEcCtD
Etoricoxib—Urethral disorder—Doxorubicin—sarcoma	0.00018	0.000815	CcSEcCtD
Etoricoxib—Nausea—Mitoxantrone—sarcoma	0.00018	0.000813	CcSEcCtD
Etoricoxib—Immune system disorder—Epirubicin—sarcoma	0.000179	0.000811	CcSEcCtD
Etoricoxib—Mediastinal disorder—Epirubicin—sarcoma	0.000179	0.000809	CcSEcCtD
Etoricoxib—Pruritus—Etoposide—sarcoma	0.000178	0.000805	CcSEcCtD
Etoricoxib—Arrhythmia—Epirubicin—sarcoma	0.000177	0.000802	CcSEcCtD
Etoricoxib—Visual impairment—Doxorubicin—sarcoma	0.000177	0.000801	CcSEcCtD
Etoricoxib—Alopecia—Epirubicin—sarcoma	0.000176	0.000794	CcSEcCtD
Etoricoxib—Mental disorder—Epirubicin—sarcoma	0.000174	0.000787	CcSEcCtD
Etoricoxib—Erythema multiforme—Doxorubicin—sarcoma	0.000174	0.000786	CcSEcCtD
Etoricoxib—Malnutrition—Epirubicin—sarcoma	0.000173	0.000782	CcSEcCtD
Etoricoxib—Erythema—Epirubicin—sarcoma	0.000173	0.000782	CcSEcCtD
Etoricoxib—Diarrhoea—Etoposide—sarcoma	0.000172	0.000779	CcSEcCtD
Etoricoxib—Eye disorder—Doxorubicin—sarcoma	0.000172	0.000777	CcSEcCtD
Etoricoxib—Tinnitus—Doxorubicin—sarcoma	0.000171	0.000775	CcSEcCtD
Etoricoxib—Flushing—Doxorubicin—sarcoma	0.000171	0.000771	CcSEcCtD
Etoricoxib—Cardiac disorder—Doxorubicin—sarcoma	0.000171	0.000771	CcSEcCtD
Etoricoxib—Flatulence—Epirubicin—sarcoma	0.00017	0.00077	CcSEcCtD
Etoricoxib—Dysgeusia—Epirubicin—sarcoma	0.000169	0.000766	CcSEcCtD
Etoricoxib—Angiopathy—Doxorubicin—sarcoma	0.000167	0.000754	CcSEcCtD
Etoricoxib—Dizziness—Etoposide—sarcoma	0.000166	0.000753	CcSEcCtD
Etoricoxib—Muscle spasms—Epirubicin—sarcoma	0.000166	0.000752	CcSEcCtD
Etoricoxib—Immune system disorder—Doxorubicin—sarcoma	0.000166	0.000751	CcSEcCtD
Etoricoxib—Mediastinal disorder—Doxorubicin—sarcoma	0.000166	0.000749	CcSEcCtD
Etoricoxib—Arrhythmia—Doxorubicin—sarcoma	0.000164	0.000742	CcSEcCtD
Etoricoxib—Vision blurred—Epirubicin—sarcoma	0.000163	0.000737	CcSEcCtD
Etoricoxib—Alopecia—Doxorubicin—sarcoma	0.000162	0.000734	CcSEcCtD
Etoricoxib—MAPK14—Signaling by VEGF—CTNNB1—sarcoma	0.000162	0.00099	CbGpPWpGaD
Etoricoxib—PTGS2—Aryl Hydrocarbon Receptor—KRAS—sarcoma	0.000162	0.000986	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—FUS—sarcoma	0.000161	0.000983	CbGpPWpGaD
Etoricoxib—MAPK14—TSH signaling pathway—HRAS—sarcoma	0.000161	0.000982	CbGpPWpGaD
Etoricoxib—Mental disorder—Doxorubicin—sarcoma	0.000161	0.000728	CcSEcCtD
Etoricoxib—Vomiting—Etoposide—sarcoma	0.00016	0.000724	CcSEcCtD
Etoricoxib—Malnutrition—Doxorubicin—sarcoma	0.00016	0.000723	CcSEcCtD
Etoricoxib—Erythema—Doxorubicin—sarcoma	0.00016	0.000723	CcSEcCtD
Etoricoxib—Anaemia—Epirubicin—sarcoma	0.00016	0.000723	CcSEcCtD
Etoricoxib—MAPK14—Oxidative Stress Induced Senescence—JUN—sarcoma	0.000159	0.000971	CbGpPWpGaD
Etoricoxib—MAPK14—Rac1/Pak1/p38/MMP-2 pathway—HRAS—sarcoma	0.000159	0.000971	CbGpPWpGaD
Etoricoxib—MAPK14—BCR signaling pathway—HRAS—sarcoma	0.000159	0.000971	CbGpPWpGaD
Etoricoxib—Agitation—Epirubicin—sarcoma	0.000159	0.000718	CcSEcCtD
Etoricoxib—Rash—Etoposide—sarcoma	0.000159	0.000718	CcSEcCtD
Etoricoxib—Dermatitis—Etoposide—sarcoma	0.000159	0.000717	CcSEcCtD
Etoricoxib—MAPK14—Senescence and Autophagy in Cancer—SRC—sarcoma	0.000158	0.000963	CbGpPWpGaD
Etoricoxib—Headache—Etoposide—sarcoma	0.000158	0.000713	CcSEcCtD
Etoricoxib—Flatulence—Doxorubicin—sarcoma	0.000158	0.000713	CcSEcCtD
Etoricoxib—Dysgeusia—Doxorubicin—sarcoma	0.000157	0.000708	CcSEcCtD
Etoricoxib—MAPK14—Toll Like Receptor 4 (TLR4) Cascade—JUN—sarcoma	0.000156	0.000952	CbGpPWpGaD
Etoricoxib—MAPK14—VEGFA-VEGFR2 Pathway—SRC—sarcoma	0.000155	0.000948	CbGpPWpGaD
Etoricoxib—Muscle spasms—Doxorubicin—sarcoma	0.000154	0.000696	CcSEcCtD
Etoricoxib—MAPK14—CDC42 signaling events—HRAS—sarcoma	0.000154	0.000937	CbGpPWpGaD
Etoricoxib—Palpitations—Epirubicin—sarcoma	0.000153	0.000691	CcSEcCtD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	0.000152	0.000925	CbGpPWpGaD
Etoricoxib—MAPK14—VEGFA-VEGFR2 Pathway—VEGFA—sarcoma	0.000151	0.000924	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—FOXO1—sarcoma	0.000151	0.000923	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—PDGFRB—sarcoma	0.000151	0.000922	CbGpPWpGaD
Etoricoxib—Cough—Epirubicin—sarcoma	0.000151	0.000682	CcSEcCtD
Etoricoxib—Vision blurred—Doxorubicin—sarcoma	0.000151	0.000682	CcSEcCtD
Etoricoxib—MAPK14—B Cell Receptor Signaling Pathway—MYC—sarcoma	0.000151	0.000919	CbGpPWpGaD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—KIT—sarcoma	0.00015	0.000915	CbGpPWpGaD
Etoricoxib—MAPK14—VEGFA-VEGFR2 Pathway—NRAS—sarcoma	0.00015	0.000912	CbGpPWpGaD
Etoricoxib—Nausea—Etoposide—sarcoma	0.00015	0.000676	CcSEcCtD
Etoricoxib—Hypertension—Epirubicin—sarcoma	0.000149	0.000675	CcSEcCtD
Etoricoxib—MAPK14—Signaling by NGF—PDGFRA—sarcoma	0.000149	0.000907	CbGpPWpGaD
Etoricoxib—Anaemia—Doxorubicin—sarcoma	0.000148	0.000669	CcSEcCtD
Etoricoxib—MAPK14—Cell-Cell communication—CTNNB1—sarcoma	0.000147	0.000898	CbGpPWpGaD
Etoricoxib—Arthralgia—Epirubicin—sarcoma	0.000147	0.000666	CcSEcCtD
Etoricoxib—Chest pain—Epirubicin—sarcoma	0.000147	0.000666	CcSEcCtD
Etoricoxib—Agitation—Doxorubicin—sarcoma	0.000147	0.000665	CcSEcCtD
Etoricoxib—MAPK14—TGF-beta Signaling Pathway—CCND1—sarcoma	0.000147	0.000896	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by VEGF—SRC—sarcoma	0.000147	0.000895	CbGpPWpGaD
Etoricoxib—Anxiety—Epirubicin—sarcoma	0.000147	0.000663	CcSEcCtD
Etoricoxib—MAPK14—TGF-beta Signaling Pathway—JUN—sarcoma	0.000147	0.000894	CbGpPWpGaD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000146	0.000661	CcSEcCtD
Etoricoxib—MAPK14—Leptin signaling pathway—HRAS—sarcoma	0.000145	0.000887	CbGpPWpGaD
Etoricoxib—Dry mouth—Epirubicin—sarcoma	0.000144	0.000651	CcSEcCtD
Etoricoxib—MAPK14—Signaling by VEGF—VEGFA—sarcoma	0.000143	0.000872	CbGpPWpGaD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—CREB1—sarcoma	0.000143	0.000871	CbGpPWpGaD
Etoricoxib—Confusional state—Epirubicin—sarcoma	0.000142	0.000643	CcSEcCtD
Etoricoxib—CYP1A2—Tryptophan metabolism—MDM2—sarcoma	0.000142	0.000864	CbGpPWpGaD
Etoricoxib—MAPK14—Glucocorticoid receptor regulatory network—TP53—sarcoma	0.000142	0.000864	CbGpPWpGaD
Etoricoxib—Palpitations—Doxorubicin—sarcoma	0.000141	0.000639	CcSEcCtD
Etoricoxib—MAPK14—Signaling by VEGF—NRAS—sarcoma	0.000141	0.000861	CbGpPWpGaD
Etoricoxib—Oedema—Epirubicin—sarcoma	0.000141	0.000638	CcSEcCtD
Etoricoxib—Anaphylactic shock—Epirubicin—sarcoma	0.000141	0.000638	CcSEcCtD
Etoricoxib—MAPK14—Developmental Biology—PTPRC—sarcoma	0.000141	0.000859	CbGpPWpGaD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—JUN—sarcoma	0.000141	0.000858	CbGpPWpGaD
Etoricoxib—Infection—Epirubicin—sarcoma	0.00014	0.000634	CcSEcCtD
Etoricoxib—Cough—Doxorubicin—sarcoma	0.00014	0.000631	CcSEcCtD
Etoricoxib—MAPK14—Toll-Like Receptors Cascades—JUN—sarcoma	0.000139	0.000848	CbGpPWpGaD
Etoricoxib—Shock—Epirubicin—sarcoma	0.000139	0.000628	CcSEcCtD
Etoricoxib—Nervous system disorder—Epirubicin—sarcoma	0.000138	0.000626	CcSEcCtD
Etoricoxib—Thrombocytopenia—Epirubicin—sarcoma	0.000138	0.000625	CcSEcCtD
Etoricoxib—Hypertension—Doxorubicin—sarcoma	0.000138	0.000625	CcSEcCtD
Etoricoxib—MAPK14—Developmental Biology—PLCG1—sarcoma	0.000138	0.00084	CbGpPWpGaD
Etoricoxib—PTGS2—Aryl Hydrocarbon Receptor—HRAS—sarcoma	0.000137	0.000838	CbGpPWpGaD
Etoricoxib—Skin disorder—Epirubicin—sarcoma	0.000137	0.00062	CcSEcCtD
Etoricoxib—MAPK14—BDNF signaling pathway—JUN—sarcoma	0.000137	0.000834	CbGpPWpGaD
Etoricoxib—Arthralgia—Doxorubicin—sarcoma	0.000136	0.000616	CcSEcCtD
Etoricoxib—Chest pain—Doxorubicin—sarcoma	0.000136	0.000616	CcSEcCtD
Etoricoxib—Anxiety—Doxorubicin—sarcoma	0.000136	0.000614	CcSEcCtD
Etoricoxib—MAPK14—BDNF signaling pathway—CTNNB1—sarcoma	0.000136	0.000827	CbGpPWpGaD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.000135	0.000612	CcSEcCtD
Etoricoxib—MAPK14—Hemostasis—PLCG1—sarcoma	0.000135	0.000824	CbGpPWpGaD
Etoricoxib—PTGS2—C-MYB transcription factor network—CCND1—sarcoma	0.000135	0.000822	CbGpPWpGaD
Etoricoxib—Anorexia—Epirubicin—sarcoma	0.000135	0.000608	CcSEcCtD
Etoricoxib—Dry mouth—Doxorubicin—sarcoma	0.000133	0.000602	CcSEcCtD
Etoricoxib—MAPK14—Cell-Cell communication—SRC—sarcoma	0.000133	0.000812	CbGpPWpGaD
Etoricoxib—Confusional state—Doxorubicin—sarcoma	0.000132	0.000595	CcSEcCtD
Etoricoxib—MAPK14—TGF-beta Signaling Pathway—SRC—sarcoma	0.000131	0.000802	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	0.000131	0.000801	CbGpPWpGaD
Etoricoxib—Oedema—Doxorubicin—sarcoma	0.000131	0.00059	CcSEcCtD
Etoricoxib—Anaphylactic shock—Doxorubicin—sarcoma	0.000131	0.00059	CcSEcCtD
Etoricoxib—Infection—Doxorubicin—sarcoma	0.00013	0.000587	CcSEcCtD
Etoricoxib—MAPK14—VEGFA-VEGFR2 Pathway—KRAS—sarcoma	0.000129	0.000785	CbGpPWpGaD
Etoricoxib—Musculoskeletal discomfort—Epirubicin—sarcoma	0.000129	0.000581	CcSEcCtD
Etoricoxib—Shock—Doxorubicin—sarcoma	0.000128	0.000581	CcSEcCtD
Etoricoxib—MAPK14—Cellular Senescence—MDM2—sarcoma	0.000128	0.000782	CbGpPWpGaD
Etoricoxib—Nervous system disorder—Doxorubicin—sarcoma	0.000128	0.000579	CcSEcCtD
Etoricoxib—Thrombocytopenia—Doxorubicin—sarcoma	0.000128	0.000578	CcSEcCtD
Etoricoxib—Insomnia—Epirubicin—sarcoma	0.000128	0.000577	CcSEcCtD
Etoricoxib—Skin disorder—Doxorubicin—sarcoma	0.000127	0.000573	CcSEcCtD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—sarcoma	0.000127	0.000772	CbGpPWpGaD
Etoricoxib—Dyspnoea—Epirubicin—sarcoma	0.000126	0.000569	CcSEcCtD
Etoricoxib—MAPK14—TCR Signaling Pathway—HRAS—sarcoma	0.000126	0.000767	CbGpPWpGaD
Etoricoxib—MAPK14—Insulin Signaling—JUN—sarcoma	0.000126	0.000766	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	0.000125	0.000765	CbGpPWpGaD
Etoricoxib—Somnolence—Epirubicin—sarcoma	0.000125	0.000567	CcSEcCtD
Etoricoxib—Anorexia—Doxorubicin—sarcoma	0.000124	0.000563	CcSEcCtD
Etoricoxib—MAPK14—EGF/EGFR Signaling Pathway—JUN—sarcoma	0.000124	0.000759	CbGpPWpGaD
Etoricoxib—Dyspepsia—Epirubicin—sarcoma	0.000124	0.000562	CcSEcCtD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—sarcoma	0.000123	0.000751	CbGpPWpGaD
Etoricoxib—Decreased appetite—Epirubicin—sarcoma	0.000123	0.000555	CcSEcCtD
Etoricoxib—MAPK14—BDNF signaling pathway—SRC—sarcoma	0.000123	0.000748	CbGpPWpGaD
Etoricoxib—Gastrointestinal disorder—Epirubicin—sarcoma	0.000122	0.000551	CcSEcCtD
Etoricoxib—MAPK14—Innate Immune System—PLCG1—sarcoma	0.000122	0.000742	CbGpPWpGaD
Etoricoxib—Fatigue—Epirubicin—sarcoma	0.000122	0.00055	CcSEcCtD
Etoricoxib—MAPK14—Signaling by VEGF—KRAS—sarcoma	0.000122	0.000741	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—JUN—sarcoma	0.000121	0.000737	CbGpPWpGaD
Etoricoxib—Constipation—Epirubicin—sarcoma	0.000121	0.000546	CcSEcCtD
Etoricoxib—Pain—Epirubicin—sarcoma	0.000121	0.000546	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.000119	0.000538	CcSEcCtD
Etoricoxib—MAPK14—B Cell Receptor Signaling Pathway—HRAS—sarcoma	0.000118	0.000722	CbGpPWpGaD
Etoricoxib—Insomnia—Doxorubicin—sarcoma	0.000118	0.000534	CcSEcCtD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—MDM2—sarcoma	0.000118	0.00072	CbGpPWpGaD
Etoricoxib—MAPK14—TGF-beta Signaling Pathway—MYC—sarcoma	0.000118	0.000718	CbGpPWpGaD
Etoricoxib—Dyspnoea—Doxorubicin—sarcoma	0.000116	0.000526	CcSEcCtD
Etoricoxib—Feeling abnormal—Epirubicin—sarcoma	0.000116	0.000526	CcSEcCtD
Etoricoxib—MAPK14—Senescence and Autophagy in Cancer—TP53—sarcoma	0.000116	0.000709	CbGpPWpGaD
Etoricoxib—Somnolence—Doxorubicin—sarcoma	0.000116	0.000525	CcSEcCtD
Etoricoxib—PTGS2—C-MYB transcription factor network—NRAS—sarcoma	0.000116	0.000707	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—ATF1—sarcoma	0.000116	0.000705	CbGpPWpGaD
Etoricoxib—Gastrointestinal pain—Epirubicin—sarcoma	0.000115	0.000522	CcSEcCtD
Etoricoxib—MAPK14—Signaling by NGF—KIT—sarcoma	0.000115	0.000703	CbGpPWpGaD
Etoricoxib—Dyspepsia—Doxorubicin—sarcoma	0.000115	0.00052	CcSEcCtD
Etoricoxib—Decreased appetite—Doxorubicin—sarcoma	0.000114	0.000513	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000113	0.00051	CcSEcCtD
Etoricoxib—Fatigue—Doxorubicin—sarcoma	0.000113	0.000509	CcSEcCtD
Etoricoxib—Urticaria—Epirubicin—sarcoma	0.000112	0.000507	CcSEcCtD
Etoricoxib—Pain—Doxorubicin—sarcoma	0.000112	0.000505	CcSEcCtD
Etoricoxib—Constipation—Doxorubicin—sarcoma	0.000112	0.000505	CcSEcCtD
Etoricoxib—MAPK14—EGF/EGFR Signaling Pathway—SRC—sarcoma	0.000112	0.000681	CbGpPWpGaD
Etoricoxib—Abdominal pain—Epirubicin—sarcoma	0.000112	0.000504	CcSEcCtD
Etoricoxib—MAPK14—Cellular Senescence—JUN—sarcoma	0.000111	0.000679	CbGpPWpGaD
Etoricoxib—MAPK14—Senescence and Autophagy in Cancer—HRAS—sarcoma	0.000111	0.000678	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—sarcoma	0.00011	0.000674	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—SRC—sarcoma	0.00011	0.000674	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—CREB1—sarcoma	0.00011	0.00067	CbGpPWpGaD
Etoricoxib—MAPK14—VEGFA-VEGFR2 Pathway—HRAS—sarcoma	0.000109	0.000668	CbGpPWpGaD
Etoricoxib—CYP3A4—Tryptophan metabolism—MDM2—sarcoma	0.000109	0.000667	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	0.000109	0.000667	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	0.000109	0.000665	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	0.000108	0.00066	CbGpPWpGaD
Etoricoxib—PTGS2—C-MYB transcription factor network—MYC—sarcoma	0.000108	0.000659	CbGpPWpGaD
Etoricoxib—Feeling abnormal—Doxorubicin—sarcoma	0.000108	0.000487	CcSEcCtD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	0.000108	0.000656	CbGpPWpGaD
Etoricoxib—Gastrointestinal pain—Doxorubicin—sarcoma	0.000107	0.000483	CcSEcCtD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—sarcoma	0.000106	0.000648	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—IL2—sarcoma	0.000105	0.000642	CbGpPWpGaD
Etoricoxib—MAPK14—Oxidative Stress Induced Senescence—TP53—sarcoma	0.000105	0.000641	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—NRAS—sarcoma	0.000104	0.000636	CbGpPWpGaD
Etoricoxib—Hypersensitivity—Epirubicin—sarcoma	0.000104	0.00047	CcSEcCtD
Etoricoxib—Urticaria—Doxorubicin—sarcoma	0.000104	0.000469	CcSEcCtD
Etoricoxib—MAPK14—Signaling by VEGF—HRAS—sarcoma	0.000103	0.00063	CbGpPWpGaD
Etoricoxib—Abdominal pain—Doxorubicin—sarcoma	0.000103	0.000467	CcSEcCtD
Etoricoxib—PTGS2—Spinal Cord Injury—CCND1—sarcoma	0.000103	0.000626	CbGpPWpGaD
Etoricoxib—Asthenia—Epirubicin—sarcoma	0.000101	0.000458	CcSEcCtD
Etoricoxib—MAPK14—Immune System—CD34—sarcoma	0.0001	0.000611	CbGpPWpGaD
Etoricoxib—Pruritus—Epirubicin—sarcoma	9.98e-05	0.000451	CcSEcCtD
Etoricoxib—PTGS2—C-MYB transcription factor network—KRAS—sarcoma	9.98e-05	0.000609	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—IL2—sarcoma	9.98e-05	0.000608	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—MYC—sarcoma	9.9e-05	0.000604	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	9.78e-05	0.000597	CbGpPWpGaD
Etoricoxib—MAPK14—EGF/EGFR Signaling Pathway—EGFR—sarcoma	9.78e-05	0.000597	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—FOXO1—sarcoma	9.78e-05	0.000596	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—MYC—sarcoma	9.71e-05	0.000592	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	9.69e-05	0.000591	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular responses to stress—MDM2—sarcoma	9.68e-05	0.000591	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—sarcoma	9.68e-05	0.00059	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—sarcoma	9.68e-05	0.00059	CbGpPWpGaD
Etoricoxib—MAPK14—TGF-beta Signaling Pathway—TP53—sarcoma	9.67e-05	0.00059	CbGpPWpGaD
Etoricoxib—Diarrhoea—Epirubicin—sarcoma	9.66e-05	0.000437	CcSEcCtD
Etoricoxib—Hypersensitivity—Doxorubicin—sarcoma	9.62e-05	0.000435	CcSEcCtD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	9.53e-05	0.000581	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—EGFR—sarcoma	9.5e-05	0.000579	CbGpPWpGaD
Etoricoxib—Asthenia—Doxorubicin—sarcoma	9.37e-05	0.000424	CcSEcCtD
Etoricoxib—Dizziness—Epirubicin—sarcoma	9.33e-05	0.000422	CcSEcCtD
Etoricoxib—MAPK14—EGF/EGFR Signaling Pathway—KRAS—sarcoma	9.24e-05	0.000564	CbGpPWpGaD
Etoricoxib—Pruritus—Doxorubicin—sarcoma	9.24e-05	0.000418	CcSEcCtD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—SRC—sarcoma	9.21e-05	0.000562	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—sarcoma	9.15e-05	0.000558	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—MDM2—sarcoma	9.08e-05	0.000554	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—KRAS—sarcoma	8.97e-05	0.000547	CbGpPWpGaD
Etoricoxib—Vomiting—Epirubicin—sarcoma	8.97e-05	0.000406	CcSEcCtD
Etoricoxib—Diarrhoea—Doxorubicin—sarcoma	8.93e-05	0.000404	CcSEcCtD
Etoricoxib—Rash—Epirubicin—sarcoma	8.9e-05	0.000402	CcSEcCtD
Etoricoxib—Dermatitis—Epirubicin—sarcoma	8.89e-05	0.000402	CcSEcCtD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—NRAS—sarcoma	8.86e-05	0.00054	CbGpPWpGaD
Etoricoxib—Headache—Epirubicin—sarcoma	8.84e-05	0.0004	CcSEcCtD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	8.77e-05	0.000535	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—SRC—sarcoma	8.7e-05	0.000531	CbGpPWpGaD
Etoricoxib—Dizziness—Doxorubicin—sarcoma	8.63e-05	0.00039	CcSEcCtD
Etoricoxib—MAPK14—Innate Immune System—FOXO1—sarcoma	8.63e-05	0.000527	CbGpPWpGaD
Etoricoxib—MAPK14—BDNF signaling pathway—HRAS—sarcoma	8.63e-05	0.000526	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—PDGFRB—sarcoma	8.62e-05	0.000526	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	8.57e-05	0.000523	CbGpPWpGaD
Etoricoxib—PTGS2—C-MYB transcription factor network—HRAS—sarcoma	8.49e-05	0.000518	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—PDGFRA—sarcoma	8.48e-05	0.000517	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—VEGFA—sarcoma	8.48e-05	0.000517	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular responses to stress—JUN—sarcoma	8.42e-05	0.000513	CbGpPWpGaD
Etoricoxib—Nausea—Epirubicin—sarcoma	8.38e-05	0.000379	CcSEcCtD
Etoricoxib—Vomiting—Doxorubicin—sarcoma	8.3e-05	0.000375	CcSEcCtD
Etoricoxib—Rash—Doxorubicin—sarcoma	8.23e-05	0.000372	CcSEcCtD
Etoricoxib—PTGS2—Spinal Cord Injury—MYC—sarcoma	8.23e-05	0.000502	CbGpPWpGaD
Etoricoxib—Dermatitis—Doxorubicin—sarcoma	8.23e-05	0.000372	CcSEcCtD
Etoricoxib—Headache—Doxorubicin—sarcoma	8.18e-05	0.00037	CcSEcCtD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	8.1e-05	0.000494	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—KDR—sarcoma	8.09e-05	0.000493	CbGpPWpGaD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—EGFR—sarcoma	8.07e-05	0.000492	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—EGFR—sarcoma	8.05e-05	0.000491	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	8.01e-05	0.000489	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—TP53—sarcoma	7.98e-05	0.000487	CbGpPWpGaD
Etoricoxib—MAPK14—Insulin Signaling—HRAS—sarcoma	7.93e-05	0.000484	CbGpPWpGaD
Etoricoxib—MAPK14—EGF/EGFR Signaling Pathway—HRAS—sarcoma	7.85e-05	0.000479	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—sarcoma	7.77e-05	0.000474	CbGpPWpGaD
Etoricoxib—Nausea—Doxorubicin—sarcoma	7.76e-05	0.000351	CcSEcCtD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—KRAS—sarcoma	7.62e-05	0.000465	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular responses to stress—VEGFA—sarcoma	7.35e-05	0.000449	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular Senescence—TP53—sarcoma	7.35e-05	0.000448	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—PTPRC—sarcoma	7.24e-05	0.000442	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	7.2e-05	0.000439	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—CREB1—sarcoma	7.09e-05	0.000432	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—PLCG1—sarcoma	7.09e-05	0.000432	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—SRC—sarcoma	7.08e-05	0.000432	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	6.98e-05	0.000426	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	6.97e-05	0.000425	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	6.91e-05	0.000422	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TLE1—sarcoma	6.91e-05	0.000422	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—NRAS—sarcoma	6.81e-05	0.000416	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—TP53—sarcoma	6.76e-05	0.000412	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—ATF1—sarcoma	6.73e-05	0.000411	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—MMP2—sarcoma	6.6e-05	0.000403	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—KIT—sarcoma	6.58e-05	0.000401	CbGpPWpGaD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—HRAS—sarcoma	6.48e-05	0.000395	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—TLE1—sarcoma	6.3e-05	0.000385	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—CREB1—sarcoma	6.26e-05	0.000382	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	6.25e-05	0.000381	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—EGFR—sarcoma	6.21e-05	0.000379	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	6.09e-05	0.000371	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—KRAS—sarcoma	5.86e-05	0.000358	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—VEGFC—sarcoma	5.83e-05	0.000356	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—NPM1—sarcoma	5.69e-05	0.000347	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	5.6e-05	0.000342	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular responses to stress—TP53—sarcoma	5.56e-05	0.000339	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	5.48e-05	0.000334	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—MDM2—sarcoma	5.18e-05	0.000316	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	5.17e-05	0.000316	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—IL2—sarcoma	5.14e-05	0.000314	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—CTNNB1—sarcoma	5.06e-05	0.000309	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—FOXO1—sarcoma	5.03e-05	0.000307	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—PDGFRB—sarcoma	5.02e-05	0.000306	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—HRAS—sarcoma	4.98e-05	0.000304	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—PDGFRA—sarcoma	4.94e-05	0.000301	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—ENO2—sarcoma	4.93e-05	0.0003	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—FLT1—sarcoma	4.66e-05	0.000284	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	4.6e-05	0.00028	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PLCG1—sarcoma	4.58e-05	0.000279	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—SRC—sarcoma	4.57e-05	0.000279	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—JUN—sarcoma	4.5e-05	0.000275	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—SRC—sarcoma	4.49e-05	0.000274	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—CTNNB1—sarcoma	4.47e-05	0.000273	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—VEGFA—sarcoma	4.45e-05	0.000272	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CXCR4—sarcoma	4.4e-05	0.000268	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—NRAS—sarcoma	4.4e-05	0.000268	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—VEGFA—sarcoma	4.37e-05	0.000267	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—ATF1—sarcoma	4.35e-05	0.000265	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—NRAS—sarcoma	4.32e-05	0.000263	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PLCG1—sarcoma	4.18e-05	0.000255	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—ENO2—sarcoma	4.13e-05	0.000252	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—HBA1—sarcoma	4.1e-05	0.00025	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—SRC—sarcoma	4.04e-05	0.000246	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CXCR4—sarcoma	4.02e-05	0.000245	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—EGFR—sarcoma	4.01e-05	0.000245	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—NRAS—sarcoma	3.89e-05	0.000237	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—ENO2—sarcoma	3.88e-05	0.000237	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—HBA1—sarcoma	3.86e-05	0.000235	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—KIT—sarcoma	3.83e-05	0.000234	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—KRAS—sarcoma	3.79e-05	0.000231	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—KRAS—sarcoma	3.71e-05	0.000227	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CREB1—sarcoma	3.65e-05	0.000222	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—EGFR—sarcoma	3.54e-05	0.000216	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PLCG1—sarcoma	3.5e-05	0.000214	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—IGF1R—sarcoma	3.42e-05	0.000208	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—KRAS—sarcoma	3.34e-05	0.000204	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—TP53—sarcoma	3.3e-05	0.000201	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PLCG1—sarcoma	3.3e-05	0.000201	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—FOXO1—sarcoma	3.25e-05	0.000198	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PDGFRB—sarcoma	3.25e-05	0.000198	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—HRAS—sarcoma	3.22e-05	0.000196	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PDGFRA—sarcoma	3.19e-05	0.000195	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—HRAS—sarcoma	3.16e-05	0.000193	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—MDM2—sarcoma	3.02e-05	0.000184	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ENO2—sarcoma	3e-05	0.000183	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—HBA1—sarcoma	2.98e-05	0.000182	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—FOXO1—sarcoma	2.97e-05	0.000181	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PDGFRB—sarcoma	2.96e-05	0.000181	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PDGFRA—sarcoma	2.91e-05	0.000178	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—HRAS—sarcoma	2.84e-05	0.000173	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ENO2—sarcoma	2.76e-05	0.000168	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—HBA1—sarcoma	2.74e-05	0.000167	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ENO2—sarcoma	2.73e-05	0.000167	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—HBA1—sarcoma	2.71e-05	0.000166	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—IL2—sarcoma	2.7e-05	0.000164	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—KDR—sarcoma	2.69e-05	0.000164	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—JUN—sarcoma	2.62e-05	0.00016	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CTNNB1—sarcoma	2.6e-05	0.000159	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PLCG1—sarcoma	2.54e-05	0.000155	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—KIT—sarcoma	2.48e-05	0.000151	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CREB1—sarcoma	2.36e-05	0.000144	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—SRC—sarcoma	2.35e-05	0.000143	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PLCG1—sarcoma	2.34e-05	0.000143	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ENO2—sarcoma	2.33e-05	0.000142	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—HBA1—sarcoma	2.32e-05	0.000142	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PLCG1—sarcoma	2.32e-05	0.000141	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—NRAS—sarcoma	2.26e-05	0.000138	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—KIT—sarcoma	2.26e-05	0.000138	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CREB1—sarcoma	2.15e-05	0.000131	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—MYC—sarcoma	2.1e-05	0.000128	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—EGFR—sarcoma	2.06e-05	0.000126	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PLCG1—sarcoma	1.98e-05	0.000121	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MDM2—sarcoma	1.95e-05	0.000119	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—KRAS—sarcoma	1.95e-05	0.000119	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ENO2—sarcoma	1.8e-05	0.00011	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—HBA1—sarcoma	1.79e-05	0.000109	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MDM2—sarcoma	1.78e-05	0.000109	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—IL2—sarcoma	1.74e-05	0.000106	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CCND1—sarcoma	1.7e-05	0.000104	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—JUN—sarcoma	1.7e-05	0.000103	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CTNNB1—sarcoma	1.68e-05	0.000103	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—HRAS—sarcoma	1.66e-05	0.000101	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CTNNB1—sarcoma	1.54e-05	9.36e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PLCG1—sarcoma	1.53e-05	9.32e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—SRC—sarcoma	1.52e-05	9.28e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—VEGFA—sarcoma	1.48e-05	9.04e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—NRAS—sarcoma	1.46e-05	8.93e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—SRC—sarcoma	1.39e-05	8.46e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MYC—sarcoma	1.36e-05	8.31e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—NRAS—sarcoma	1.33e-05	8.14e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—EGFR—sarcoma	1.33e-05	8.13e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—KRAS—sarcoma	1.26e-05	7.68e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MYC—sarcoma	1.24e-05	7.58e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—EGFR—sarcoma	1.22e-05	7.42e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—KRAS—sarcoma	1.15e-05	7.01e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TP53—sarcoma	1.12e-05	6.83e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—HRAS—sarcoma	1.07e-05	6.53e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—HRAS—sarcoma	9.77e-06	5.96e-05	CbGpPWpGaD
